Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$375.33 USD

375.33
927,702

+2.21 (0.59%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $374.55 -0.78 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?

by Zacks Equity Research

Sector ETF report for IHI

Is Trending Stock Intuitive Surgical, Inc. (ISRG) a Buy Now?

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Why Is Integra (IART) Up 10.2% Since Last Earnings Report?

by Zacks Equity Research

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wall Street Analysts Think Intuitive Surgical, Inc. (ISRG) Is a Good Investment: Is It?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Intuitive Surgical, Inc. (ISRG) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Is Most-Watched Stock Intuitive Surgical, Inc. (ISRG) Worth Betting on Now?

by Zacks Equity Research

Zacks.com users have recently been watching Intuitive Surgical, Inc. (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

HCA Healthcare's (HCA) Q3 Earnings Miss on High Expense Level

by Zacks Equity Research

HCA Healthcare's (HCA) Q3 results were hurt by an increase in salaries and benefits expenses. Management presently estimates 2023 EPS to be within $17.80-$18.50, compared with the prior-view of $17.70-$18.90 per share.

Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Robust

by Zacks Equity Research

Intuitive Surgical's (ISRG) third-quarter results reflect healthy demand for procedures, partially offset by lower system sales. Higher pricing boosted procedure sales.

Here's What Key Metrics Tell Us About Intuitive Surgical, Inc. (ISRG) Q3 Earnings

by Zacks Equity Research

The headline numbers for Intuitive Surgical, Inc. (ISRG) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Intuitive Surgical, Inc. (ISRG) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 3.55% and 1.37%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Intuitive Surgical (ISRG) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.

Why Intuitive Surgical, Inc. (ISRG) Could Beat Earnings Estimates Again

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Intuitive Surgical, Inc. (ISRG) Rises Higher Than Market: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $295.68, denoting a +1.93% change from the preceding trading day.

Intuitive Surgical, Inc. (ISRG) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Intuitive Surgical, Inc. (ISRG) closed at $294.98 in the latest trading session, marking a +0.92% move from the prior day.

Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Intuitive Surgical, Inc. (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors continue to remain optimistic about CVS Health (CVS) due to the new acquisitions and the strong execution of the pharmacy business.

Zimmer Biomet (ZBH) Gains From ROSA Sales Growth Amid FX Woes

by Zacks Equity Research

Zimmer Biomet (ZBH) plans to work on the overall shift of the company's legacy knee systems to a fully rounded-out Persona portfolio.

Abbott (ABT) Rides on Nutrition Recovery Amid Low Testing Sales

by Zacks Equity Research

Abbott's (ABT) Nutrition business has started showing signs of recovery since the beginning of 2023.

Is Intuitive Surgical (ISRG) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Intuitive Surgical, Inc. (ISRG) and Artivion (AORT) have performed compared to their sector so far this year.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors continue to remain optimistic about Hologic (HOLX), backed by the Breast Health business' performance and international execution.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

by Zacks Equity Research

Investors are increasingly optimistic about Labcorp (LH) due to its progress in hospital partnerships.

Neogen (NEOG) Gains From Strong Segmental Sales, Innovation

by Zacks Equity Research

Within the biosecurity portfolio, Neogen (NEOG) continues to record solid growth in cleaners, disinfectants and rodenticides.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

STERIS' (STE) healthcare segment benefits from procedure recovery, boosting investors' optimism.

Here's Why You Should Buy Align Technology (ALGN) Stock Now

by Zacks Equity Research

The rapid expansion of Align Technology's (ALGN) business in international markets remains a key growth driver.